United States · Seed startup

Who invested in KeborMed

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 15 Nov 2026

$1.9Mraised across 1 round since 2022, from 1 source

Latest round
Seed, $1.9MMay 2022
Investors
0
See who backed them

The rounds

  1. May 2022
    Seed$1.9M

    No investor was named in the report.

    Source recordedSEC filing: $1.9M sold, first sale Aug 2021

Funding filed with regulators

KeborMed filed 3 raises, $2.9M in all. Filings say how much was sold and to how many investors; they never name the investors.

  1. May 2022$845K5 investorsotherof $1.5M offeredSEC Form D
  2. Aug 2021$1.9M7 investorsequityof $2.5M offeredSEC Form D
  3. Jun 2018$125K2 investorsotherof $500K offeredSEC Form D

Founders and team

From the SEC filings it signed: 2 on the team.

  • Radu IancuExecutive Officer, Director, Promoteri
  • Warren GoldenbergExecutive Officer, Director, Promoteri

On the board, as filediRobert Immerman

Also claim to have backed them

This firm lists KeborMed as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Third Act VenturesVC firmPer its own site

Quick answers about KeborMed

How much has KeborMed raised?

KeborMed has raised $1.9M across 1 round since 2022.

When did KeborMed last raise?

KeborMed's most recent round was a Seed of $1.9M in May 2022.

What was KeborMed's biggest round?

Its most recent round, $1.9M in May 2022, is also its largest on record.

What stage is KeborMed at?

KeborMed's latest named round is a Seed, in May 2022.

Where is KeborMed based?

KeborMed is based in the United States.

Companies like KeborMed

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.